GastroMARK®

GastroMARK® (ferumoxsil) is AMAG Pharmaceuticals' oral gastrointestinal (GI) imaging agent for delineation of the bowel. Images of organs and tissues in the abdomen using MRI without contrast agents can be difficult to read because the abdominal organs and tissues cannot be easily distinguished from the loops of the bowel. GastroMARK® flows through and darkens the bowel when ingested. By more clearly identifying the intestinal loops, GastroMARK® enhances the ability to distinguish the bowel from adjacent tissues and organs in the upper gastrointestinal tract.

GastroMARK® is marketed in the United States by Covidien, Ltd. (formerly Tyco Healthcare, Ltd. and Mallinckrodt, Inc.) For more information regarding Gastromark® please contact Covidien, Ltd. at (888) 744-1414. Gastromark® is marketed in Western Europe and Brazil by Guerbet S.A. under the tradename Lumirem™. In Europe Gastromark® is approved for rectal administration to delineate the lower intestinal system.

Gastromark is a trademark of Mallinckrodt Inc. (a subsidiary of Covidien, Ltd.) registered in the U.S.